Myron, Yes, ZONA was at the TX conference but it does not seem that Wessels was! Here is a release about it:
Trade Stock for $9.99
Texas Biomedical Investment Conference in Houston February 18-19 to Feature
Presentations by 13 Companies, Panel Discussion by Texas Heart Institute Researchers
BusinessWire, Monday, February 02, 1998 at 06:16
HOUSTON, Texas--(BW HealthWire)--Feb. 2, 1998--
Program Will Include Seminar at The University of Texas
M.D. Anderson Cancer Center With Prominent Researchers
Thirteen leading Texas-based biomedical companies will host an
invitation-only conference for analysts and institutional investors
Feb. 18-19 at the Wyndham Warwick Hotel in Houston.
The conference offers investors a unique opportunity to learn
about investment opportunities in the Texas region, one of the top
dozen areas in the country with a strong community of life science
companies.
In addition to presentations by the companies, the conference
will highlight research underway at two prominent medical centers in
Houston. On Wednesday, Feb. 18, James T. Willerson, M.D., medical
director and chief of cardiology at the Texas Heart Institute, will
lead a panel discussion on the expansion of biotechnology around the
medical center.
The other panelists will include Dr. Edward T.H. Yeh, director,
Division of Molecular Medicine and vice chairman, Division of
Cardiology at The University of Texas-Houston Medical School; and Dr.
H. Vernon "Skip" Anderson, associate professor and director of
interventional cardiology at The University of Texas-Houston Medical
School.
On Thursday, Feb. 19, attendees will be transported to a special
seminar at The University of Texas M.D. Anderson Cancer Center, titled
"Making Cancer History(TM): New Molecular Targets for the
Diagnosis and Treatment of Cancer." John Mendelsohn, M.D., the
center's president, will moderate the session.
Other speakers will include Dr. Frederick F. Becker, vice
president for research; Dr. Jack A. Roth, professor and chairman,
Dept. of Thoracic and Cardiovascular Surgery; Dr. Gabriel
Lopez-Berenstein, professor of medicine and internist; and Dr. Gordon
B. Mills, chairman, molecular oncology.
There also will be a media/biomedical industry session on Feb. 18
at the Wyndham Warwick Hotel. Tom Kowalski, president of the Texas
Healthcare and Biosciences Institute, will present results of a report
on Texas biomedical companies titled "A Profile of Progress: The Texas
Healthcare Technology Industry."
The session will also feature Joan Hamilton, editor of
Recombinant Capital's on-line magazine Signals, Martin Lindenberg,
chairman, Steering Committee of the Houston Technology Center, and Jim
C. Kollaer, president and CEO of Greater Houston Partnership.
The hosting companies include:
Amarillo Biosciences, Inc. (NASDAQ:AMAR), based in Amarillo, TX,
is developing oral and topical interferons as treatments for a variety
of diseases, including Sjogren's syndrome, fibromyalgia, hepatitis B,
hepatitis C and several skin diseases. A low dose oral interferon
alpha is in Phase III testing for Sjogren's syndrome.
Aronex Pharmaceuticals, Inc. (NASDAQ/NNM:ARNX) is an emerging
biopharmaceutical company developing innovative medicines for the
treatment of cancer and life-threatening infectious diseases.
Located in The Woodlands, the company has four products in
ongoing clinical development: Nyotran(TM) an antifungal agent,
Atragen(TM) for acute promyelocytic leukemia, Annamycin for the
treatment of cancer and Zintevir(TM) for HIV.
BioNumerik Pharmaceuticals, Inc., a private company headquartered
in San Antonio, is using an innovative, proprietary technology
platform for the discovery and clinical development of new small
molecule based pharmaceuticals to treat cancer.
BioNumerik's "mechanism based approach" to drug discovery
integrates medicine, quantum physics, synthetic chemistry,
pharmaceutical sciences and supercomputing. Complex proprietary
pharmaceutical software is used to simulate molecular interactions and
drug transformations in the body.
BioNumerik has two compounds in Phase I clinical trials and a
third compound in late preclinical development.
Cytoclonal Pharmaceuticals, Inc. (NASDAQ:CYPH) is a
biopharmaceutical company based in Dallas. Its major emphasis is its
paclitaxel (Taxol(R)(1)) program consisting of a patented fungal
paclitaxel production process using fermentation and paclitaxel
specific genes, and a patented potential new use of paclitaxel for
polycystic kidney disease, which potentially could double the present
$1 billion market.
Other programs involve a patented gene (LCG) associated with
forms of lung cancer and a mycobacterial vaccine delivery system for
cancer and infectious diseases.
(1) Marketed by Bristol-Myers Squibb
GENEMEDICINE, Inc. is a leader in the development of a novel
class of gene therapy products designed for the treatment or
prevention of serious diseases. Gene medicines deliver genetic
instructions to targeted cells in the body to produce therapeutic
proteins or desired immune responses.
The company's core technology includes lipid-, peptide-,
carbohydrate- and polymer-based gene delivery systems, each able to be
applied to specific clinical targets, and gene expression systems to
regulate the production of multiple genes.
The GENEMEDICINE patent portfolio includes recently issued U.S.
and European claims that broadly cover the use for gene therapy of any
cationic lipid combined with DNA and administered by injection or
inhalation, the most common routes of administration.
ILEX Oncology, Inc. (NASDAQ:ILXO), located in San Antonio, is a
drug development company focused exclusively on the development of
drugs for the treatment and prevention of cancer. ILEX provides
pharmaceutical and biotechnology companies with compounds for their
pipelines, as well as drug development and manufacturing services on a
contract basis.
ILEX has a portfolio of seven anticancer drugs in clinical
testing, with others in earlier stages of development. In addition to
its chemotherapeutic compounds, ILEX has two chemoprevention agents
under development to stop the occurrence, progression or recurrence of
cancer.
The company's close association with cancer research and
treatment institutions allows access to both the opinion leaders and
patients necessary for the development of oncology drugs.
Introgen Therapeutics, Inc., a privately-held company based in
Austin, is developing gene therapy products to treat cancer in vivo.
The company has two products in clinical trials that target cancers
linked to two genes, the p53 tumor suppresser gene and the K-ras
oncogene.
Rhone-Poulenc Rorer Pharmaceuticals is funding worldwide research
and development of these products under two collaborative agreements
with Introgen. Introgen's core technologies were developed at The
University of Texas M.D. Anderson Cancer Center.
Lexicon Genetics Inc. is a private genomics pharmaceutical
company using high-throughput gene targeting to define gene function
on a commercial scale. Lexicon is developing two areas of genomics:
defining gene function and identifying drug targets.
The Woodlands-based company has created OmniBank, a library of
thousands of mouse embryonic stem cell clones that are catalogued by
the DNA sequence of the single gene mutated in each clone. The company
will use selected models to create a new line of mutant mice specific
to the genes of interest, thereby enabling researchers to determine
the function of the genes.
LifeCell Corporation (NASDAQ:LIFC) is a bioengineering company
engaged in the development and commercialization of tissue
regeneration and cell preservation products. LifeCell's first
commercial product, AlloDerm(R) acellular dermal graft, is used in
reconstructive plastic, dental and burn surgery.
In addition to AlloDerm grafts, the company's current tissue
graft development plans include the LifeCell(R) heart valve (under
exclusive agreement with Medtronic, Inc. (NYSE:MDT)), and vascular
grafts. LifeCell's product development programs also include
ThromboSol(TM), a formulation for extending the shelf life of
transfusable platelets.
Tanox Biosystems, Inc. is a private biotechnology research and
development company based in Houston. Tanox is developing novel
biopharmaceuticals for treatment of diseases involving or affecting
the human immune system, such as allergic diseases, HIV infection,
inflammation and asthma, and certain cancers and chronic infections.
The company has a joint development agreement with Genentech,
Inc. and Novartis Pharma A.G. for an anti-IgE antibody product, E25,
for treatment of allergic diseases. Pivotal trials are in progress for
allergic rhinitis and Phase III trials in allergic asthma are
scheduled to begin early in 1998.
Texas Biotechnology Corp. (AMEX:TXB) is developing a new
generation of therapeutics focused on preserving the functional
integrity of the vascular system. NOVASTAN(R) (argatroban), an
injectable anticoagulant in co-development with SmithKline Beecham,
has been submitted for approval to the FDA for heparin-induced
thrombocytopenia.
Texas Biotechnology is also conducting Phase II studies of its
endothelin-A receptor antagonist in congestive heart failure and its
selectin antagonist in asthma. The company is located adjacent to the
Texas Medical Center in Houston.
ViroTex Corporation, a privately held company, is a developer of
proprietary drug delivery systems that use the skin and mucosa as the
primary site of delivery. To maximize return on investment, ViroTex
focuses its resources on the development of broad-based drug delivery
platforms, which will serve as the basis for multiple product
applications.
The company has validated three novel drug delivery platforms,
which relate to localized and systemic delivery of pharmaceutical
compounds for a variety of indications. The company's first product
was launched in 1996. ViroTex is based in The Woodlands Research
Forest, north of Houston, Texas.
Zonagen, Inc. (NASDAQ:ZONA; Pacific:ZNG), located in The
Woodlands, is a biopharmaceutical company engaged in the research,
development and marketing of products for conditions and diseases
associated with the human reproductive system. Zonagen's lead product
candidate, Vasomax(TM), is an oral pill treatment for male erectile
dysfunction.
The company also is developing new approaches to contraception,
including zona pellucida-based vaccines in collaboration with Schering
AG, treatments for urological diseases such as benign prostatic
hyperplasia and prostate cancer, and an adjuvant to enhance the
effectiveness of vaccines.
Zonagen markets and distributes a variety of third-party
fertility-related products through its wholly owned subsidiary,
Fertility Technologies, Inc.
Leading sponsors of the Texas investment conference are Arthur
Andersen, Andrews & Kurth, Business Wire, Frost Bank, Gerard Klauer
Mattison, PPD Pharmaco, Silicon Valley Bank, Willis Corroon of Texas,
and Wilson Sonsini Goodrich. Management of the conference is being
provided by Russell-Welsh, Inc., a San Mateo, California-based
communications firm specializing in the lifesciences industry.
CONTACT: RUSSELL-WELSH, INC.
Barbara Heineback, 650/312-0700, x 21
KEYWORD: TEXAS CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICINE PHARMACEUTICAL BANKING
TRADESHOW
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
Copyright 1998, Business Wire
Companies or Securities discussed in this article:
Symbol
Name
NASDAQ:AMAR
Amarillo Biosciences
NASDAQ:CYPH
Cytoclonal Pharmaceuticals Inc
NASDAQ:ILXO
Ilex Oncology Inc
NASDAQ:LIFC
Lifecell Corp
NYSE:MDT
Medtronic Inc
AMEX:TXB
Texas Biotech Corp
NASDAQ:ZONA
Zonagen Inc
c 1998 Quote.com, Inc. All Rights Reserved. |
